By IDSE News Staff
The FDA is expecting to decide on Merck’s request for two supplemental New Drug Applications (sNDAs) for its cyto-megalovirus (CMV) drug letermovir (Prevymis): one on June 5 and the other Sept. 7, 2023.
The agency not only accepted the applications but also granted them Priority Review.